Calyxt joins a select network of synthetic biology companies, high-profile academic institutions, research-focused nonprofits, and US government agencies dedicated to innovation and growth in the bioeconomy.

Roseville, Minnesota.And the November 1, 2022 /PRNewswire/ — Today, Calyxt, Inc. (NASDAQ: CLXT), a company specializing in plant synthetic biology, announced that it has become a member of the Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense that started a Manufacturing Innovation Institute dedicated to advancing biomanufacturing across the country.

BioMADE membership includes a diverse network of large corporations, innovative startups, universities, and non-profit research organizations to raise and secure the United States’ global leadership in advanced biomanufacturing. Calyxt intends to work with BioMADE and a list of collaborating organizations nationwide to achieve BioMADE’s goal of securing America’s future through biomanufacturing innovation, education, and collaboration.

“We look forward to collaborating with BioMADE and its member organizations to advance the development of our plant-based technology into sustainable bioproducts,” said Calyxt President and CEO. Michael A. Carr. “Biomanufacturing and the broader bioeconomy ecosystem is poised for significant growth, and by joining BioMADE, we are positioning Calixt to be a part of that growth.”

“BioMADE is delighted to welcome Calyxt to its select membership network,” said BioMADE’s Chief Technology Officer. Melanie Tomczak. “Calyxt’s strength and knowledge in engineering plant-based solutions will bring significant experience and expertise to the BioMADE community, as we collectively build the US biomanufacturing ecosystem. In pursuing this mission, we are pleased to have Calyxt among our collaborators.”

In September, the White House announced funding over 2 dollars billion to launch the National Biotechnology and Biomanufacturing Initiative to lower prices, create good jobs, strengthen supply chains, improve health outcomes, and reduce carbon emissions.

BioMADE also provides its members with access to federal funding, industry collaboration, and broader participation in supporting the development of biomanufacturing technologies to enhance critical industrial competitiveness in the United States.

About BioMADE:

BioMADE is one of the nine Institutes for Manufacturing Innovation affiliated with the Department of Defense. BioMADE and its members are also striving to create a more robust, resilient, bio-based supply chain for the United States to become more self-sufficient in the global market. In addition, BioMADE and its members are committed to building a diverse and globally competitive science, technology, engineering, and mathematics (STEM) workforce that is willing and ready to fill new positions. Learn more about BioMADE, including how your organization can join us to become a member, by Visit their website or follow them LinkedIn And the Twitter.

About Calext:

Calixt (NASDAQ: CLXT) is a plant-based synthetic biology company. The company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative, high-value phytochemicals for use in customer materials and products. As botanical solutions, the company’s synthetic biology products can be used to help customers achieve sustainability and financial goals. Calyxt’s diverse offerings are primarily delivered through its BioFactory™ production system. For more information, visit

forward-looking statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements in this communication include statements about the Company’s participation in and contribution to BioMADE and the opportunities afforded to the Company through membership in BioMADE. These and other forward-looking statements are expectations and projections about future events and trends based on the Company’s current expectations, goals and intentions and are based on current assumptions. The Company’s actual results, level of activity, performance, or achievements may be materially different from those expressed, implied, or expected by forward-looking statements due to a variety of factors, including, but not limited to: the potential impact of cost reduction and other measures. which focus on cash for liquidity management; increased competition, including competition from a broader group of synthetic biology companies; competition for customers, partners and licensees and the successful implementation of development and licensing agreements; disruptions to the main facilities of Calyxt or its partners; Changes in customer preferences and market acceptance of its products; Changes in market consensus on the attributes required for a product to be considered “sustainable”; the impact of negative events during development; Disruptions in supply chains, including the inputs of raw materials for its vital plant; and other significant factors discussed in Part 1, Section 1A, “Risk Factors” in a Company’s Filings with the Securities and Exchange Commission, listed in Part 1, Section 1A of its annual report on Form 10-K for the year ended December 31, 2021which was submitted to the SEC on March 3, 2022, and its subsequent reports on Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Any forward-looking statements made by the Company’s management are based solely on information currently available and speak only as of the date of this report. Except as required by securities and other applicable laws, the Company assumes no obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.

Calyxt Media Contact:
Brennan BurksCalyxt, Inc.
(651) 724-5788
[email protected]

Calyxt Investor Relations Contact:
Kimberly Minarovic / Cameron Willis
Argot Partners
(212) 600-1902
[email protected]

SOURCE Calyxt, Inc.

Leave a Reply